Introduction
Diamond-Blackfan Anemia (DBA, MIM#105650) is a rare congenital, inherited bone-marrow-failure syndrome (IBMFS), characterized by normochromic macrocytic anemia, reticulocytopenia, and absence or insufficiency of erythroid precursors in normocellular bone marrow.
1 DBA was first reported by Josephs (1936) and refined as a distinct clinical entity by Diamond and Blackfan (1938) . Recent study shows that the cellular defect in DBA fibroblasts is primarily caused by a reduced proliferation and a prolonged cell-cycle corresponding to the bone marrow characteristics of DBA. 2 DBA is a rare disease with a frequency of two to seven per million live births and has no ethnic or gender predilection. 1 Approximately 90% of affected patients typically present in infancy or early childhood, although patients with a "non-classical" mild phenotype are diagnosed later in life. 3, 4 Although macrocytic anemia is a prominent feature of DBA, the disease is also characterized by growth retardation and congenital anomalies, including craniofacial, upper limb/hand, cardiac, and genitourinary malformations that are present in approximately half of the patients. [3] [4] [5] In addition, DBA patients have a predisposition to malignancy including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and osteogenic sarcoma. 3 Diagnosis of DBA is often difficult because incomplete phenotypes and wide variability of clinical expression are present. [4] [5] [6] The central hematopoietic defect is characterized by an enhanced sensitivity of hematopoietic progenitors to apoptosis along with evidence of stress erythropoiesis, including elevations in fetal hemoglobin and mean red cell volume (MCV). 2 The majority of patients exhibit an increase in erythrocyte adenosine deaminase activity. 7 Proteins are universally synthesized in ribosomes. This macromolecular ribonucleoprotein machinery consists of two subunits: one small and one large. The mammalian ribosome is comprised of 4 RNAs and 80 ribosomal proteins. 8 The first DBA gene, mutated in approximately 25% of DBA patients, was identified as RPS19, which is located at chromosome 19q13.2 and encodes the protein belonging to the small subunit of the ribosome. 9, 10 Haploinsufficiency of the RPS19 gene product has been demonstrated in a subset of cases 11 and appears to be sufficient to cause DBA. The RPS19 protein plays an important role in 18S rRNA maturation and small ribosomal subunit synthesis in human cells. 12 In this study, we screened 49 Japanese DBA patients (45 probands) for mutations of the six known DBA genes and RPS14, which has been implicated in the 5q-syndrome, a subtype of myelodysplastic syndrome characterized by a defect in erythroid differentiation.
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Design and Methods
Patients
Forty-nine patients were studied in order to define the frequency and type of mutations of RP genes associated with DBA in Japan. Eight patients were from multiplex families, whereas 41 were from families with only one affected patient. 
RP gene analysis
DNA was extracted from peripheral blood using a standard proteinase K, phenol and chloroform protocol. 21 The polymerase chain reaction (PCR) was used to amplify fragments from genomic DNA using primer sets designed to amplify the coding exons and exon/intron boundaries of the RPS19, RPS17, RPS24, RPS14, RPL5, RPL11 and RPL35A. PCR products were directly sequenced in the forward and/or reverse direction using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Tokyo, Japan) on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Analysis of RPS19 was performed by determining the genomic DNA sequence of the non-coding first exon, with flanking regions, and the 450-base pair (bp) sequence upstream of the first exon (5'UTR) for each DNA sample as previously described. 5 
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To clarify the sequence of heterozygous insertion/deletion sequence variations, the respective PCR products were cloned into a TA pCR 2.1 vector (Invitrogen, Carlsbad, CA, USA) and their sequences were confirmed.
Genotype-phenotype correlation and statistical analysis
Physical abnormalities were evaluated from a viewpoint of correlations with genotype in Japanese DBA patients. Although growth retardation can be modified by several factors such as steroid therapy, chronic anemia, and iron overload, the patients were considered pathognomonic for DBA if there was marked growth retardation below -3 standard deviation (SD). Response to treatment is usually seen within 1 month of treatment in DBA, but the prediction for response has not been reported previously. 1, 3 We also examined the correlation between genotype and responsiveness to the first round of steroid therapy. Associations between two groups of variables were assessed with Fisher's exact test. All tests were two-sided and significant for p < 0.05. Data were analyzed with SPSS 11.0J software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 49 patients (45 probands) were available for analysis. The male to female ratio was 1:1.2.
Forty-one index cases were classified as sporadic without unexplained anemia in first-degree relatives, while the remaining 8 patients were from 4 families. All patients were Japanese except two cases, case 10 was Chinese and case 23 was a Brazilian of Japanese extraction. Case 15 had a Filipina mother and Japanese father.
Genetics
RPS19
Six different mutations were detected in 6 probands out of 45 families (13%) ( 
RPL5 and RPL11!
The human RPL5 gene consists of eight exons and is located on chromosome 1. Four novel mutations were found among the 45 probands (9%) ( Table 1 ). The median age at presentation of the index cases with RPL5 mutations was 10 months. A deletion of two nucleotides was found in case 10, and an insertion of one nucleotide was found in case 65, each affecting the reading frame. Two cases (cases 41 and 55) had point mutations that resulted in a loss of the translation initiation codon.
The human RPL11 gene, which consists of six exons, is also located on chromosome 1. All exons and exon/intron boundaries were PCR-amplified and sequenced in DBA patients who were negative for mutations in RPS19 and RPL5. Two mutations (4%) were found, and they were diagnosed at 18 and 20 months old, respectively( Table 1) . A deletion of two nucleotides was found in case 9, and a deletion of one nucleotide was found in one case 23, each leading to a shift in the reading frame and the introduction of a premature stop codon.
RPS17!
The RPS17 gene is located on chromosome 15, and consists of five exons. RPS17 mutations are rare and have been reported in only 2 DBA patients. A novel 1-nucleotide deletion in RPS17 was identified in 1 patient (2%), resulting in the introduction of a premature stop codon ( Table 1 ). The patient with the RPS17 mutation (case 56) was born to healthy non-consanguineous parents and diagnosed as DBA at a month old.
He responded to the initial steroid treatment, and had a course of steroid-dependent therapy. No physical anomalies were seen in this patient.
RPL35A, RPS24 and RPS14
Mutations in RPS24 and RPL35A are rare and have been reported in only 8 and 6 patients with DBA, respectively. DBA patients were screened for RPS24 and RPL35A, in addition to RPS14, which is implicated in 5q-syndrome. No mutations were detected in RPS24, RPL35A or RPS14 in Japanese DBA patients.
In total, sequence changes were found in 4 out of 7 screened RP genes ( Table 2) . Mutations in RPS19, RPS17, RPL5, and RPL11 were detected in 13%, 2%, 9%, and 4% of the probands, respectively. The frequency of RP gene mutations in Japanese DBA patients was 29%.
Genotype-phenotype correlations
Congenital anomalies
Patient characteristics are summarized in Table 3 . Anomalies associated with DBA were found in 2 7
patients (55%). Sixteen were affected with two or more malformations (33%). All 7 patients with an RPS19 mutation had physical anomalies, and 4 of them had multiple anomalies. In contrast, clinical data from European and American DBA patients showed that the frequency of malformations was 31% in patients with RPS19 mutations, which is not significantly different from that of the entire DBA population. 26 
RPS19
mutations are characterized by a wide variability of phenotypic expression. 26 A mutation is frequently associated with various degrees of anemia, different responses to treatment, and dissimilar malformations.
Even various family members having the same mutation in RPS19 present with different clinical expressions.
Cases 30, 44 and 43 harbored the same RPS19 mutations reported in multi-families (p.R62Q, p.R62W, p.0). 6, 10, 11, [22] [23] [24] [25] [26] [27] Comparable to previous observations, no consistent clinical features were found within patients from different families displaying mutations in RPS19. For example, the father of case 30 harboring the same mutation had no finger anomalies, although case 30 had syndactyly and thumb polydactyly.
Consistent with reports that patients with RPL5 and RPL11 mutations are at high risk for developing malformations, 17,18 all 4 patients with RPL5 mutations had physical anomalies. Furthermore, three of them had multiple physical anomalies, especially case 41, who had very severe congenital heart disease ( Table 3) .
One of 2 patients with RPL11 mutations had physical anomalies. In contrast, of the 35 patients with no mutations, physical anomalies were seen in 15 (43%).
Nine patients had craniofacial anomalies. Of these, one had RPS19 mutations and two had RPL5 mutations, while the remaining patients had no mutations. Gazda et al. suggested an association between RPL5/RPL11 mutation and cleft lip and/or palate. 17 The Diamond-Blackfan Anemia Registry (DBAR) of North America also suggested that the DBA phenotype associated with cleft lip/palate is caused by non-RPS19 mutations. 4 In our data, the frequency of cleft palate was significantly different between RPL5-mutated and RPL5 non-mutated groups (p < 0.05): cleft palate was seen in 3 patients, 2 patients with RPL5 mutations and only one patient with RPL5 non-mutated patients.
Thumb anomaly was seen in 6 patients, 4 of whom had RPS19 mutations while 2 had RPL5 mutations.
There was a statistically significant difference between RPS19-mutated and RPS19 non-mutated groups in the frequency of thumb anomalies (p < 0.05). Flat thenar was seen in one patient with an RPL5 mutation. In contrast to previous reports on patients with RPL11 mutations, thumb anomalies were not found in our patients. SFD was seen in 7 patients (14%): one had an RPS19 mutation, one had an RPL11 mutation, and the four others had no mutations. None of the patients with RPL5 mutations were born SFD.
Therapeutic response
Corticosteroids and transfusion are the mainstays of DBA treatment. 1, 3 Of 45 patients evaluable for first treatment response, 73% were responsive to steroid therapy, 8% were non-responsive and 16% were never treated with steroids. The proportions of patients that responded to the first steroid treatment were 5/5 (RPS19), 2/3 (RPL5), 1/2 ( RPL11), 1/1 ( RPS17), and 22/27 (no mutation). There were no significant differences in the response rates among these patients.
Sixty-nine percent of patients received red blood cell transfusions. Of 48 patients available for therapy in follow-up, 8 patients (17%) were transfusion-dependent, 18 patients (37%) were steroid-dependent, and 18 patients (37%) were transfusion-independent with no other treatment. Three patients received bone marrow transplants and were alive and well (Table 3) . Malignancy was detected in one case (case 50 proband), who developed MDS one year after diagnosis of DBA.
Discussion
This is the first report of an investigation of DBA patients in Japan. Thirteen types of mutations were detected in 4 RP genes. These mutations occurred in 29% of Japanese DBA patients. Mutations in RPS19, which have been found in 25% of patients in Western countries, 26 were detected in only 6 of 45 probands (13%) in Japan, and three of these mutations were unique. Novel mutations in RPL5 (4 probands; 9%), RPL11 (2; 4%) and RPS17 (1; 2%) were identified. The frequencies of mutations in RPL5, RPL11 and RPS17
were very similar to those in Western countries. [16] [17] [18] [19] These results may suggest that a lower incidence of mutations in RP genes in Japanese patients with DBA is due to a lower incidence of RPS19 mutations, although we might miss the large deletions or re-arrangements in this study.
Physical abnormalities and growth retardation were detected in 55% of Japanese DBA patients, similar to previous reports in Western countries. [4] [5] [6] Recent studies suggest that the patients with RPL5 mutation are more likely to have physical malformations including craniofacial, thumb, and heart anomalies. 17, 18 Remarkably, patients with RPL5 mutations tend to have cleft lip and/or palate or cleft soft palate, isolated or in combination with other physical abnormalities. 17, 18 We found that 3 of 4 patients with RPL5 mutations had multiple physical malformations, and 2 had cleft palate, whereas only one patient without an RPL5 mutation had cleft palate. In the general population, 0.1% to 0.2% of children are born with cleft lip and/or palate. 28 Our data, and those from previous findings, suggest that PRL5 mutations are associated with multiple physical abnormalities, especially cleft lip and/or palate.
Cmejla et al. reported that 87.5% of RPL5-mutated patients were born SFD, whereas only 42.9% of RPS19-mutated patients were born SFD. 18 However, in our data, SFD was seen in 7 patients, and all of them 9
were RPL5-non-mutated patients. Our data suggest that RPL5 mutations in Japanese DBA patients have no relevance to SFD, and may be a unique characteristic of Japanese DBA.
According to recent studies, the frequency of malformation, particularly thumb anomalies, in RPS19-mutated patients, was relatively low compared to RPL5-or RPL11-mutated patients. [22] [23] [24] 29 In Italian DBA patients, the risk of malformation was 7-fold higher in RPL5-mutated patients compared to RPS19-mutated patients. 29 In contrast, all of the Japanese DBA patients with RPS19 mutations had one or more malformations. The frequency of thumb anomalies was significantly higher in patients with RPS19 mutations, as well as in patients with RPL5 mutations, compared to other groups of patients.
Although steroid therapy is one of the established treatments for DBA, the mechanism of action is unknown and reliable prediction of response to initial steroid therapy is not available. 1,3 RPS19 mutation status has not been predictive of response in any series. 3 In our data, the responsiveness to first steroid therapy in Japanese DBA patients was as good as that reported in Western countries. 1, 3 In this study, the comparison showed no significant differences of responsiveness to initial steroid therapy between RPS19-mutated and RPS19-non-mutated groups, or between RPS19-mutated and other RP gene mutated groups.
In summary, we found that heterozygous mutations in either RPS19, RPL5, RPL11 or RPS17 were present in 29% of Japanese DBA patients. No mutations were detected in RPS14, RPS24 or RPL35A. We observed a slightly lower frequency of mutations in ribosomal protein genes in DBA patients when compared to previous reports from Western countries, although the data from both populations are based on a relatively low number of patients and values showing significant differences between populations are missing . Our data suggest an association between RPL5 mutation and malformation, especially cleft palate, and between RPS19 mutation and malformation, particularly thumb anomalies. This study also suggests that no association exists between RPL5 mutation and SFD or between RPS19 mutation and non-responsiveness to initial steroid therapy in Japanese DBA patients.
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